Evidence map›Paper›PMID 39989320›Full record

ArticleACS synthetic biology2025

CnRed: Efficient, Marker-free Genome Engineering of

Simon Arhar, Johanna Pirchner, Holly Stolterfoht-Stock, Karin Reicher, Robert Kourist, Anita Emmerstorfer-Augustin

Abstract read
In one paragraph

Article in ACS synthetic biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Simon ArharAustrian Centre of Industrial Biotechnology, acib GmbH, 8010 Graz, Austria.
Johanna PirchnerAustrian Centre of Industrial Biotechnology, acib GmbH, 8010 Graz, Austria.
Holly Stolterfoht-StockAustrian Centre of Industrial Biotechnology, acib GmbH, 8010 Graz, Austria.
Karin ReicherAustrian Centre of Industrial Biotechnology, acib GmbH, 8010 Graz, Austria.
Robert KouristAustrian Centre of Industrial Biotechnology, acib GmbH, 8010 Graz, Austria.ORCID 0000-0002-2853-3525
Anita Emmerstorfer-AugustinAustrian Centre of Industrial Biotechnology, acib GmbH, 8010 Graz, Austria.ORCID 0000-0002-3392-8839

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to its ability to utilize carbon dioxide, native intracellular accumulation of bioplastic precursors, and a high protein content, the bacterium

Indexed as

Bacteriophage lambdaCupriavidus necatorGene EditingGenetic EngineeringElectroporationEscherichia coliGenome, BacterialPlasmidsRecombination, GeneticCupriavidus necatorelectroporationgenetic engineeringlambda Redphytaserecombineering

Identifiers

PMID39989320
PMCPMC11934132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.